Donald Trump is leading in the polls and could become the Republican nominee and maybe even President. He has not been specific on healthcare. I asked Scottish-Canadian-Californian healthcare futurist Ian Morrison to conduct an interview with Trump, figuring that Morrison would have an in with Trump given Trump’s praise for Scottish and Canadian healthcare. Not entirely coincidentally Ian is my old boss & mentor and will be a keynote speaker at this Fall’s Health 2.0 conference–Matthew Holt
Ian Morrison: Thanks for making time Mr. Trump, I was asked to interview you on healthcare because I am Scottish and your mother was a Scot.
Donald Trump: Yes she was, a beautiful person. I love Scotland. I own Turnberry, the best golf resort in Europe. I built a magnificent new course near Aberdeen. The Scots love me, I get along with the Scots.
Morrison: Actually, Mr. Trump, with all due respect, they think you are a bit of an asshole and were offended when you told them not to build a wind farm off shore from your new golf course because you thought it would spoil the view for your American visitors.
Trump: (Angrily). Look, the problem with the Scots is they don’t win any more. When was the last time you won…Braveheart, right? When was that 1800 or something?
Morrison: 1305
Trump: See. Losers for 800 years. So don’t talk to me about the Scots winning.
Morrison: So why did you point to Scotland and Canada as good examples of healthcare.Continue reading…

This past December after eight months of formal work the Senate Finance Committee’s “Bipartisan Chronic Care Working Group” released for comment a 30-page memo outlining 23 policy options to improve chronic care quality, patient outcomes and cost efficiency. While the Committee is not endorsing any of the options identified members will likely not stray far from this list when they move to drafting legislative language next month at least in part because members insist the bill must be cost neutral. Committee members and staff should be applauded for their effort to date since both political parties have been disinterested in adding policies to improve the Medicare program. (Last year’s MACRA bill was largely unpaid for and aptly described by Henry Aaron in the New England Journal of Medicine as a log rolling exercise.) On balance, the Committee’s effort should leave Medicare stakeholders cautiously hopeful. While some of the proposed options are obvious and incrementally beneficial, others might aid in innovating care delivery and in advancing CMS’s efforts to improve quality and value payment.
We have been talking about Precision Medicine for a long time now but so far we are still in the infancy of using genetics to impact medical decision making. The human genome was sequenced in 2003,with the promise of rapid medical advances and genetically tailored treatments. However, development and adoption of these treatments has been slow. Today with the advent of large cohorts, and in particular, the construction of the US Government’s Precision Medicine Cohort,